Alzheimer's drug prescribed off-label could pose risk for some

(University of California - Los Angeles Health Sciences) Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news